Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Travere Therapeutics stock

TVTX
US89422G1076
A2QHYP

Price

0
Today +/-
-0
Today %
-0 %

Travere Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Travere Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Travere Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Travere Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Travere Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Travere Therapeutics Stock Price History

DateTravere Therapeutics Price
11/29/20240 undefined
11/27/20240 undefined
11/26/20240 undefined
11/25/20240 undefined
11/22/20240 undefined
11/21/20240 undefined
11/20/20240 undefined
11/19/20240 undefined
11/18/20240 undefined
11/15/20240 undefined
11/14/20240 undefined
11/13/20240 undefined
11/12/20240 undefined
11/11/20240 undefined
11/8/20240 undefined
11/7/20240 undefined
11/6/20240 undefined
11/5/20240 undefined
11/4/20240 undefined

Travere Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Travere Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Travere Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Travere Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Travere Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Travere Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Travere Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Travere Therapeutics’s growth potential.

Travere Therapeutics Revenue, EBIT and net profit per share

DateTravere Therapeutics RevenueTravere Therapeutics EBITTravere Therapeutics Net Income
2029e0 undefined0 undefined0 undefined
2028e0 undefined0 undefined0 undefined
2027e0 undefined0 undefined0 undefined
2026e0 undefined0 undefined0 undefined
2025e0 undefined0 undefined0 undefined
2024e0 undefined0 undefined0 undefined
20230 undefined0 undefined0 undefined
20220 undefined0 undefined0 undefined
20210 undefined0 undefined0 undefined
20200 undefined0 undefined0 undefined
20190 undefined0 undefined0 undefined
20180 undefined0 undefined0 undefined
20170 undefined0 undefined0 undefined
20160 undefined0 undefined0 undefined
20150 undefined0 undefined0 undefined
20140 undefined0 undefined0 undefined
20130 undefined0 undefined0 undefined
20120 undefined0 undefined0 undefined
20110 undefined0 undefined0 undefined
20100 undefined0 undefined0 undefined
20090 undefined0 undefined0 undefined
20080 undefined0 undefined0 undefined

Travere Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0000000000000000000000
----------------------
----------------------
0000000000000000000000
0000000000000000000000
----------------------
0000000000000000000000
----------------------
Details

Keystats

ⓘ

Revenue and Growth

The Travere Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Travere Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2008200920102011201220132014201520162017201820192020202120222023
                               
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
                               
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Travere Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Travere Therapeutics's financial health and stability.

Assets

Travere Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Travere Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Travere Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Travere Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2008200920102011201220132014201520162017201820192020202120222023
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
0000000000000000
----------------
0000000000000000
0000000000000000
0000000000000000
0000000000000000

Travere Therapeutics stock margins

The Travere Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Travere Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Travere Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Travere Therapeutics's sales revenue. A higher gross margin percentage indicates that the Travere Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Travere Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Travere Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Travere Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Travere Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Travere Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Travere Therapeutics Margin History

Travere Therapeutics Gross marginTravere Therapeutics Profit marginTravere Therapeutics EBIT marginTravere Therapeutics Profit margin
2029e0 %0 %0 %
2028e0 %0 %0 %
2027e0 %0 %0 %
2026e0 %0 %0 %
2025e0 %0 %0 %
2024e0 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %
20110 %0 %0 %
20100 %0 %0 %
20090 %0 %0 %
20080 %0 %0 %

Travere Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Travere Therapeutics earnings per share therefore indicates how much revenue Travere Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Travere Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Travere Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Travere Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Travere Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Travere Therapeutics Revenue, EBIT and net profit per share

DateTravere Therapeutics Sales per ShareTravere Therapeutics EBIT per shareTravere Therapeutics Earnings per Share
2029e0 undefined0 undefined0 undefined
2028e0 undefined0 undefined0 undefined
2027e0 undefined0 undefined0 undefined
2026e0 undefined0 undefined0 undefined
2025e0 undefined0 undefined0 undefined
2024e0 undefined0 undefined0 undefined
20230 undefined0 undefined0 undefined
20220 undefined0 undefined0 undefined
20210 undefined0 undefined0 undefined
20200 undefined0 undefined0 undefined
20190 undefined0 undefined0 undefined
20180 undefined0 undefined0 undefined
20170 undefined0 undefined0 undefined
20160 undefined0 undefined0 undefined
20150 undefined0 undefined0 undefined
20140 undefined0 undefined0 undefined
20130 undefined0 undefined0 undefined
20120 undefined0 undefined0 undefined
20110 undefined0 undefined0 undefined
20100 undefined0 undefined0 undefined
20090 undefined0 undefined0 undefined
20080 undefined0 undefined0 undefined

Travere Therapeutics business model

Travere Therapeutics, Inc is a pharmaceutical company specializing in rare diseases. It was founded in 2019 and is headquartered in San Diego, California. Travere is tirelessly working to develop innovative therapies to improve the lives of patients with rare diseases. History Travere Therapeutics was formed from the merger of Retrophin, Inc and privately held company Censa Pharmaceuticals, Inc. Retrophin was founded in 2011 by Martin Shkreli and had difficulties in developing therapies for rare diseases. Shkreli later left the company and Retrophin focused on developing therapies for multiple rare diseases. In 2019, Retrophin merged with Censa Pharmaceuticals to form Travere Therapeutics, a company solely dedicated to rare diseases. Business Model Travere Therapeutics' business model is to develop innovative therapies for rare diseases that address an unmet medical need. With a strong focus on research and development, the company is working to discover, develop, and market new and life-changing therapies. Travere Therapeutics has a strong pipeline of drugs and medications in various stages of clinical development. This pipeline includes therapies for rare diseases such as nephrotic syndromes, mucopolysaccharidosis, lipid disorders, and others. Divisions Travere Therapeutics specializes in two business areas: pharmaceuticals and diagnostics. Pharmaceutical Business Travere Therapeutics' pharmaceutical business includes researching, developing, and marketing therapies for rare diseases. The company has a strong focus on research and development and has a pipeline of drugs and therapies aimed at improving the lives of patients with rare diseases. Diagnostics Business Travere Therapeutics' diagnostics business focuses on diagnostic tests for rare diseases. The company has partnerships with labs and facilities around the world specializing in diagnostics and genetics to ensure accurate diagnosis of patients with rare diseases. Products Travere Therapeutics offers a variety of products and therapies in different stages of development. Here are some of the key products the company offers: · Isturisa: a medication for the treatment of Cushing's syndrome, a rare disease caused by overproduction of the hormone cortisol. · Re-PLAI: a medication for the treatment of nephrotic syndromes, a group of disorders caused by kidney dysfunction. · Enzyme Replacement Therapy (ERT): an approach to treating inherited metabolic disorders by administering missing enzymes. Conclusion Travere Therapeutics is an innovative company specializing in developing therapies for rare diseases. The company has a strong pipeline of drugs and the expertise to develop therapies for patients who are underserved by traditional medications. With a focus on research and diagnostics, the company has the potential to improve the lives of millions of patients with rare diseases. Travere Therapeutics is one of the most popular companies on Eulerpool.com.

Travere Therapeutics SWOT Analysis

Strengths

Travere Therapeutics Inc has several strengths that contribute to its success. These include:

  • Strong research and development capabilities
  • Innovative pipeline of potential therapeutics
  • Experienced and knowledgeable management team
  • Solid financial position

Weaknesses

Despite its strengths, Travere Therapeutics Inc also has weaknesses that need to be addressed:

  • Limited product portfolio
  • Reliance on external partnerships for certain drug development projects
  • Vulnerability to regulatory changes and uncertainties
  • Highly competitive industry

Opportunities

Travere Therapeutics Inc has opportunities to further expand and improve its position in the market:

  • Potential for strategic collaborations and partnerships
  • Growing global demand for innovative therapies
  • Advancements in technology that can enhance drug discovery and development processes

Threats

However, there are also several threats that Travere Therapeutics Inc should be aware of and address:

  • Intense competition from established and emerging biopharmaceutical companies
  • Stringent regulatory approvals and compliance requirements
  • Potential failure of clinical trials and setbacks in drug development
  • Economic and political factors impacting the healthcare industry

Travere Therapeutics Revenue by Segment

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Travere Therapeutics Revenue by Segment

Segmente2023202220212020201920182017
Net product sales127.54 M USD200.53 M USD210.78 M USD----
License and collaboration revenue17.7 M USD11.5 M USD16.71 M USD----

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Travere Therapeutics Revenue by Segment

Segmente2023202220212020201920182017
Bile acid products-102.56 M USD95.65 M USD89.44 M USD79.7 M USD75.07 M USD-
Tiopronin products-97.97 M USD115.12 M USD108.88 M USD---
Thiola----95.64 M USD89.18 M USD-
Thiola License------82.31 M USD
Bile Acid Products------72.63 M USD
FILSPARI29.21 M USD------

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Travere Therapeutics Revenue by Segment

Segmente2023202220212020201920182017
Clinical Development Activity14.4 M USD------
Active Pharmaceutical Ingredient3.3 M USD------
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Travere Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Travere Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Travere Therapeutics shares outstanding

The number of shares was Travere Therapeutics in 2023 — This indicates how many shares 74.267 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Travere Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Travere Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Travere Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Travere Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Travere Therapeutics stock splits

In Travere Therapeutics's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Travere Therapeutics.

Travere Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20240 0  (-1 %)2024 Q3
6/30/20240 0  (-3.62 %)2024 Q2
3/31/20240 0  (-74.14 %)2024 Q1
12/31/20230 0  (20.65 %)2023 Q4
9/30/20230 0  (-703.57 %)2023 Q3
6/30/20230 0  (2.89 %)2023 Q2
3/31/20230 0  (-6.34 %)2023 Q1
12/31/20220 0  (6.01 %)2022 Q4
9/30/20220 0  (-23.68 %)2022 Q3
6/30/20220 0  (-17.48 %)2022 Q2
1
2
3
4
...
5

Eulerpool ESG Scorecard© for the Travere Therapeutics stock

Eulerpool World ESG Rating (EESG©)

68/ 100

🌱 Environment

55

👫 Social

95

🏛️ Governance

54

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Travere Therapeutics shareholders

%
Name
Stocks
Change
Date
8.74942 % Armistice Capital LLC7,500,00006/30/2024
8.59776 % Deep Track Capital LP7,370,00006/30/2024
7.70368 % The Vanguard Group, Inc.6,603,591353,9276/30/2024
7.18857 % BlackRock Institutional Trust Company, N.A.6,162,04262,5146/30/2024
5.22896 % Rock Springs Capital Management LP4,482,26570,2826/30/2024
5.09546 % Macquarie Investment Management4,367,830-245,2296/30/2024
3.89834 % Morgan Stanley & Co. LLC3,341,6532,7006/30/2024
3.67052 % Emerald Advisers LLC3,146,368567,9579/30/2024
3.44066 % Millennium Management LLC2,949,335747,4066/30/2024
3.19260 % State Street Global Advisors (US)2,736,696-773,9819/30/2024
1
2
3
4
5
...
10

Travere Therapeutics Executives and Management Board

Dr. Eric Dube

(50)
Travere Therapeutics President, Chief Executive Officer, Director (since 2019)
Compensation 5.75 M

Dr. Jula Inrig

(48)
Travere Therapeutics Chief Medical Officer
Compensation 2.87 M

Mr. Christopher Cline

(39)
Travere Therapeutics Chief Financial Officer
Compensation 2.33 M

Dr. William Rote

(60)
Travere Therapeutics Senior Vice President - Research and Development
Compensation 2.03 M

Mr. Peter Heerma

(52)
Travere Therapeutics Chief Commercial Officer
Compensation 2.01 M
1
2
3

Travere Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Thermo Fisher Scientific Stock
Thermo Fisher Scientific
SupplierCustomer0,580,760,590,660,770,48
Ligand Pharmaceuticals Stock
Ligand Pharmaceuticals
SupplierCustomer0,520,790,530,700,280,38
Vifor Pharma Stock
Vifor Pharma
SupplierCustomer0,520,08-0,34-0,350,350,24
Omnicom Stock
Omnicom
SupplierCustomer0,470,480,31-0,11-0,100,14
Albireo Pharma Stock
Albireo Pharma
SupplierCustomer-0,530,120,63-0,02-0,400,01
1

Most common questions regarding Travere Therapeutics

What values and corporate philosophy does Travere Therapeutics represent?

Travere Therapeutics Inc represents values of integrity, innovation, and patient-centricity. With a strong corporate philosophy focused on improving the lives of patients with rare and serious diseases, Travere Therapeutics is committed to delivering transformative therapies. The company places high importance on scientific excellence and collaboration to drive its research and development efforts. By prioritizing the needs of patients and continuously striving for advancements in healthcare, Travere Therapeutics aims to make a meaningful impact in the lives of individuals affected by rare diseases.

In which countries and regions is Travere Therapeutics primarily present?

Travere Therapeutics Inc is primarily present in multiple countries and regions around the world. The company is focused on providing innovative therapies to patients with rare and serious diseases. With a global presence, Travere Therapeutics operates in key markets such as the United States, Europe, and Canada. Through strategic partnerships and collaborations, the company aims to enhance patient access to its transformative treatments worldwide.

What significant milestones has the company Travere Therapeutics achieved?

Travere Therapeutics Inc, formerly known as Retrophin Inc, has achieved several significant milestones. Firstly, the company successfully developed and gained approval for its leading product, Sparsentan, a treatment for focal segmental glomerulosclerosis and IgA nephropathy. Additionally, Travere Therapeutics Inc expanded its portfolio through the acquisition of Censa Pharmaceuticals and Orphan Technologies. The company has also demonstrated its commitment to enhancing patient care by partnering with leading research institutions and patient advocacy groups. Furthermore, Travere Therapeutics Inc has continued to invest in research and development to deliver innovative therapies for rare and underserved diseases.

What is the history and background of the company Travere Therapeutics?

Founded in 1997, Travere Therapeutics Inc is a leading biopharmaceutical company focused on improving the lives of patients with rare and underserved diseases. Formerly known as Retrophin, the company underwent a rebranding in 2019 to reflect its commitment to advancing transformative therapies. With a strong emphasis on innovation, Travere Therapeutics is dedicated to developing and commercializing novel treatments to address critical unmet medical needs. The company's diverse pipeline includes investigational drugs designed to target various diseases, including rare genetic disorders and kidney diseases. Travere Therapeutics Inc continues to build upon its rich history of scientific expertise and collaborations to drive breakthrough solutions for patients worldwide.

Who are the main competitors of Travere Therapeutics in the market?

The main competitors of Travere Therapeutics Inc in the market include Actelion Pharmaceuticals Ltd, Alexion Pharmaceuticals Inc, and Ultragenyx Pharmaceutical Inc.

In which industries is Travere Therapeutics primarily active?

Travere Therapeutics Inc is primarily active in the biopharmaceutical industry.

What is the business model of Travere Therapeutics?

The business model of Travere Therapeutics Inc revolves around developing and commercializing transformative therapies to address rare and serious diseases. By focusing on areas of high unmet medical need, Travere Therapeutics aims to make a meaningful impact on the lives of patients and their families. Leveraging its expertise in research and development, the company strives to identify potential treatment options and deliver innovative solutions to improve patient outcomes. Travere Therapeutics Inc aims to collaborate with healthcare professionals, regulators, and patient advocacy groups to ensure that its therapies reach those who need them the most, providing hope and improving quality of life.

What is the P/E ratio of Travere Therapeutics 2024?

The P/E ratio cannot be calculated for Travere Therapeutics at the moment.

What is the P/S ratio of Travere Therapeutics 2024?

The P/S cannot be calculated for Travere Therapeutics currently.

What is the Quality Investing of Travere Therapeutics?

The Quality Investing for Travere Therapeutics is 5/10.

What is the revenue of Travere Therapeutics 2024?

The revenue cannot currently be calculated for Travere Therapeutics.

How high is the profit of Travere Therapeutics 2024?

The profit cannot currently be calculated for Travere Therapeutics.

What is the business model of Travere Therapeutics

Travere Therapeutics Inc is a biotechnology company focused on developing innovative therapies for rare metabolic disorders and kidney diseases. Their business model includes offering products and services in various sectors. One of the key sectors of Travere Therapeutics is drug development. The company is working on developing drug candidates for various diseases, including Mucopolysaccharidosis Type II (MPS II), a rare genetic disorder caused by enzyme deficiencies. Travere Therapeutics has obtained approval for Vimizim and Kyndrisa, the only two approved therapies for MPS II. The company is also developing therapies for other rare metabolic disorders and kidney diseases. Another important sector of Travere Therapeutics is the provision of support services for patients and medical professionals. The company offers training on the treatment of rare metabolic disorders and kidney problems, as well as medical information and assistance with medication procurement. Additionally, the company collaborates closely with patient organizations and other medical institutions to raise awareness about rare diseases. Travere Therapeutics also operates an extensive research and development (R&D) department. Their research focuses on identifying new therapies and drug candidates that have the potential to effectively treat certain diseases. The company's R&D department also invests in clinical trials to assess the effectiveness and safety of their medications and promote the approval of new therapies. Travere Therapeutics also has a strong commitment to collaborating with other companies and organizations in the industry. The company works with scientists and researchers around the world to develop innovative therapies and treatment methods. They also collaborate with regulatory authorities to advance their medications through clinical trials and an effective approval pipeline. The business model of Travere Therapeutics is based on a comprehensive approach to treating rare metabolic disorders and kidney problems. The company offers innovative therapies, support services for patients and medical professionals, and extensive research and development. Through their collaboration with other companies and organizations, Travere Therapeutics aims to realize their vision of better healthcare for all.

What is the Travere Therapeutics dividend?

Travere Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Travere Therapeutics pay dividends?

The dividend cannot currently be calculated for Travere Therapeutics or the company does not pay out a dividend.

What is the Travere Therapeutics ISIN?

The ISIN of Travere Therapeutics is US89422G1076.

What is the Travere Therapeutics WKN?

The WKN of Travere Therapeutics is A2QHYP.

What is the Travere Therapeutics ticker?

The ticker of Travere Therapeutics is TVTX.

How much dividend does Travere Therapeutics pay?

Over the past 12 months, Travere Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Travere Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Travere Therapeutics?

The current dividend yield of Travere Therapeutics is .

When does Travere Therapeutics pay dividends?

Travere Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Travere Therapeutics?

Travere Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Travere Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Travere Therapeutics located?

Travere Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Travere Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Travere Therapeutics from 12/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/2/2024.

When did Travere Therapeutics pay the last dividend?

The last dividend was paid out on 12/2/2024.

What was the dividend of Travere Therapeutics in the year 2023?

In the year 2023, Travere Therapeutics distributed 0 USD as dividends.

In which currency does Travere Therapeutics pay out the dividend?

The dividends of Travere Therapeutics are distributed in USD.

All fundamentals about Travere Therapeutics

Our stock analysis for Travere Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Travere Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.